Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase-Reference-Cited by-同舟云学术

Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase

Published:2007-11 Issue:22 Volume:17 Page:6326-6329
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Ballard Peter,Barlaam Bernard C.,Bradbury Robert H.,Dishington Allan,Hennequin Laurent F.A.,Hickinson D. Mark,Hollingsworth Ian M.,Kettle Jason G.,Klinowska Teresa,Ogilvie Donald J.,Pearson Stuart E.,Scott James S.,Suleman Abid,Whittaker Robin,Williams Emma J.,Wood Robin,Wright Lindsay

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference17 articles.

1. Topics in Medicinal Chemistry (Cancer);Wallace,2007

2. Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor

3. 5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase

4. Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket

5. N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase Inhibitor

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The conjugation of targeted therapy and image-guided phototdynamic therapy of cancer in vitro and in vivo;Bioorganic Chemistry;2020-07

2. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo;Bioorganic & Medicinal Chemistry;2019-10

3. Research progress in quinazoline derivatives as multi-target tyrosine kinase inhibitors;Heterocyclic Communications;2018-02-23

4. SAR and QSAR study on the bioactivities of human epidermal growth factor receptor-2 (HER2) inhibitors;SAR and QSAR in Environmental Research;2017-02-01

5. Standing on the shoulders of giants: a retrospective analysis of kinase drug discovery at AstraZeneca;Drug Discovery Today;2016-10